Breast cancer
Conditions
Brief summary
The feasibility of ovarian stimulation combining Tamoxifen with recombinant FSH as part of fertility preservation prior to chemotherapy for breast cancer will be assessed on the basis of the number of oocytes and/or embryos obtained per patient included.
Detailed description
Evaluation of the average time taken to start chemotherapy: time (in days) between the day of the consultation with the oncologist and the day of administration of the first chemotherapy treatment, Overall survival / event-free survival at 10 years., Number of pregnancies obtained: number of positive beta HCG and number of clinical pregnancies., Ancillary study (Nantes patients only): Analysis of plasma concentrations of tamoxifen and its metabolites, 4 -hydroxytamoxifen, N - desmethyltamoxifen and endoxifen
Interventions
DRUGNOLVADEX 10 mg
DRUGcomprimé pelliculé
Sponsors
Institut De Cancerologie De L Ouest
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of ovarian stimulation combining Tamoxifen with recombinant FSH as part of fertility preservation prior to chemotherapy for breast cancer will be assessed on the basis of the number of oocytes and/or embryos obtained per patient included. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the average time taken to start chemotherapy: time (in days) between the day of the consultation with the oncologist and the day of administration of the first chemotherapy treatment, Overall survival / event-free survival at 10 years., Number of pregnancies obtained: number of positive beta HCG and number of clinical pregnancies., Ancillary study (Nantes patients only): Analysis of plasma concentrations of tamoxifen and its metabolites, 4 -hydroxytamoxifen, N - desmethyltamoxifen and endoxifen | — |
Countries
France
Outcome results
None listed